H. Lundbeck A/S ended 2020 with revenue of DKK 17.7 billion (€2.4 billion), up by 4% from a year earlier on the back of double-digit sales increases for four of its medicines for brain diseases. The 2020 revenue figure also includes DKK 93 million from sales of Vyepti, a new product for the prevention of chronic migraine. Vyepti was launched in the US in April.
